Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?
- 1 September 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 38 (9), 2459-2463
- https://doi.org/10.1161/strokeaha.106.477133
Abstract
Background and Purpose - Patients with atrial fibrillation have a varied risk of stroke, depending on age and comorbid conditions. The objective of this study was to assess the predictive value of stroke risk classification schemes and to identify patients with atrial fibrillation who are at substantial risk of stroke despite optimal anticoagulant therapy. Methods - Seven recognized classification schemes - the American College of Chest Physicians 2001, American College of Chest Physicians 2004, Stroke Prevention in Atrial Fibrillation (SPAF), Atrial Fibrillation Investigators, Framingham, van Walraven, and CHADS(2) - were compared for their ability to predict ischemic stroke in patients receiving anticoagulant therapy. Data came from the Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation III and V trials, which compared the efficacy of adjusted-dose warfarin and the direct thrombin inhibitor ximelagatran (36 mg twice daily) in preventing thromboembolic events in 7329 patients with chronic or paroxysmal nonvalvular atrial fibrillation who were at moderate or high risk of ischemic stroke. The main outcome measure was ischemic stroke, as determined by a central event adjudication committee. Results - During 11 245 patient-years of follow-up, 159 patients had an ischemic stroke (1.4%/year). As indicated by c statistics and hazard ratios, 3 of the classification schemes predicted stroke significantly better than chance: Framingham (c = 0.64), CHADS2 (c = 0.65), and SPAF (c = 0.61). Conclusions - In a large cohort of atrial fibrillation patients at moderate or high risk of ischemic stroke treated with warfarin or ximelagatran, the CHADS2, SPAF, and Framingham schemes had greater predictive accuracy than chance. This predictive ability may allow clinicians to target high-risk patients for more aggressive interventionKeywords
This publication has 21 references indexed in Scilit:
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006
- Anticoagulation Therapy in Atrial Fibrillation in Combination With Acute Myocardial Infarction Influences Long-Term OutcomeCirculation, 2005
- Prospective dosing of warfarin based on cytochrome P-450 2C9 genotypeThrombosis and Haemostasis, 2005
- Selecting Patients With Atrial Fibrillation for AnticoagulationCirculation, 2004
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)American Heart Journal, 2003
- ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summaryJournal of the American College of Cardiology, 2001
- A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve ReplacementNew England Journal of Medicine, 1993
- SOME SIMPLE APPROXIMATE TESTS FOR POISSON VARIATESBiometrika, 1953